Display options
Cite
Repova K, Aziriova S, Krajcirovicova K, et al. Cardiovascular therapeutics: A new potential for anxiety treatment?. Med Res Rev. 2022;doi: 10.1002/med.21875.
Repova, K., Aziriova, S., Krajcirovicova, K., & Simko, F. (2022). Cardiovascular therapeutics: A new potential for anxiety treatment?. Medicinal research reviews, . https://doi.org/10.1002/med.21875
Repova, Kristina, et al. "Cardiovascular therapeutics: A new potential for anxiety treatment?." Medicinal research reviews vol. (2022). doi: https://doi.org/10.1002/med.21875
Repova K, Aziriova S, Krajcirovicova K, Simko F. Cardiovascular therapeutics: A new potential for anxiety treatment?. Med Res Rev. 2022 Jan 06; doi: 10.1002/med.21875. Epub 2022 Jan 06. PMID: 34993995.
Copy Download .nbib Format: NLM
Share it on

Med Res Rev. 2022 Jan 06; doi: 10.1002/med.21875. Epub 2022 Jan 06.

Cardiovascular therapeutics: A new potential for anxiety treatment?.

Medicinal research reviews

Kristina Repova, Silvia Aziriova, Kristina Krajcirovicova, Fedor Simko

Affiliations

  1. Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
  2. 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
  3. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.

PMID: 34993995 DOI: 10.1002/med.21875

Abstract

Besides the well-recognized risk factors, novel conditions increasing cardiovascular morbidity and mortality are emerging. Undesirable emotions and behavior such as anxiety and depression, appear to participate in worsening cardiovascular pathologies. On the other hand, deteriorating conditions of the heart and vasculature result in disturbed mental and emotional health. The pathophysiological background of this bidirectional interplay could reside in an inappropriate activation of vegetative neurohormonal and other humoral systems in both cardiovascular and psychological disturbances. This results in circulus vitiosus potentiating mental and circulatory disorders. Thus, it appears to be of utmost importance to examine the alteration of emotions, cognition, and behavior in cardiovascular patients. In terms of this consideration, recognizing the potential of principal cardiovascular drugs to interact with the mental state in patients with heart or vasculature disturbances is unavoidable, to optimize their therapeutic benefit. In general, beta-blockers, central sympatholytics, ACE inhibitors, ARBs, aldosterone receptor blockers, sacubitril/valsartan, and fibrates are considered to exert anxiolytic effect in animal experiments and clinical settings. Statins and some beta-blockers appear to have an equivocal impact on mood and anxiety and ivabradine expressed neutral psychological impact. It seems reasonable to suppose that the knowledge of a patient's mood, cognition, and behavior, along with applying careful consideration of the choice of the particular cardiovascular drug and respecting its potential psychological benefit or harm might improve the individualized approach to the treatment of cardiovascular disorders.

© 2022 The Authors. Medicinal Research Reviews published by Wiley Periodicals LLC.

Keywords: aldosterone antagonists; angiotensin II type 1 receptor blockers; angiotensin-converting enzyme inhibitors; anxiety; beta-blockers; ivabradine; sacubitril/valsartan; statins

References

  1. The Lancet. GBD 2017: a fragile world. Lancet. 2018;392(10159):1683. - PubMed
  2. Emdin CA, Odutayo A, Wong CX, Tran J, Hsiao AJ, Hunn BHM. Meta-analysis of anxiety as a risk factor for cardiovascular disease. Am J Cardiol. 2016;118(4):511-519. - PubMed
  3. Holwerda SW, Luehrs RE, Gremaud AL, et al. Relative burst amplitude of muscle sympathetic nerve activity is an indicator of altered sympathetic outflow in chronic anxiety. J Neurophysiol. 2018;120(1):11-22. - PubMed
  4. Reeves JW, Fisher AJ, Newman MG, Granger DA. Sympathetic and hypothalamic-pituitary-adrenal asymmetry in generalized anxiety disorder. Psychophysiology. 2016;53(6):951-957. - PubMed
  5. Won E, Kim YK. Stress, the Autonomic Nervous System, and the immune-kynurenine pathway in the etiology of depression. Curr Neuropharmacol. 2016;14(7):665-673. - PubMed
  6. Kumar A, Chanana P. Role of nitric oxide in stress-induced anxiety: from pathophysiology to therapeutic target. Vitam Horm. 2017;103:147-167. - PubMed
  7. Pavel J, Benicky J, Murakami Y, Sanchez-Lemus E, Saavedra JM. Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo. Ann N Y Acad Sci. 2008;1148:360-366. - PubMed
  8. Wei TM, Wang L. Anxiety symptoms in patients with hypertension: a community-based study. Int J Psychiatry Med. 2006;36(3):315-322. - PubMed
  9. Broomfield NM, Quinn TJ, Abdul-Rahim AH, Walters MR, Evans JJ. Depression and anxiety symptoms post-stroke/TIA: prevalence and associations in cross-sectional data from a regional stroke registry. BMC Neurol. 2014;14:198. - PubMed
  10. Davies SJC, Ghahramani P, Jackson PR, et al. Association of panic disorder and panic attacks with hypertension. Am J Med. 1999;107(4):310-316. - PubMed
  11. Boyle SH, Michalek JE, Suarez EC. Covariation of psychological attributes and incident coronary heart disease in U.S. Air Force veterans of the Vietnam war. Psychosom Med. 2006;68(6):844-850. - PubMed
  12. Jakobsen AH, Foldager L, Parker G, Munk-Jørgensen P. Quantifying links between acute myocardial infarction and depression, anxiety and schizophrenia using case register databases. J Affect Disord. 2008;109(1-2):177-181. - PubMed
  13. Ostir GV, Goodwin JS. High anxiety is associated with an increased risk of death in an older tri-ethnic population. J Clin Epidemiol. 2006;59(5):534-540. - PubMed
  14. Chen YH, Hu CJ, Lee HC, Lin HC. An increased risk of stroke among panic disorder patients: a 3-year follow-up study. Can J Psychiatry. 2010;55(1):43-49. - PubMed
  15. Miles HHW, Barrabee EL, Finesinger JE. Evaluation of psychotherapy, with a follow-up study of 62 cases of anxiety neurosis. Psychosom Med. 1951;13(2):83-105. - PubMed
  16. Pedersen SS, von Känel R, Tully PJ, Denollet J. Psychosocial perspectives in cardiovascular disease. Eur J Prev Cardiol. 2017;24(3_suppl):108-115. - PubMed
  17. Park H, Rhee J, Park K, Han JS, Malinow R, Chung C. Exposure to stressors facilitates long-term synaptic potentiation in the Lateral Habenula. J Neurosci. 2017;37(25):6021-6030. - PubMed
  18. Ray A, Gulati K, Rai N. Stress, anxiety, and immunomodulation: a pharmacological analysis. Vitam Horm. 2017;103:1-25. - PubMed
  19. Bali A, Jaggi AS. Angiotensin as stress mediator: role of its receptor and interrelationships among other stress mediators and receptors. Pharmacol Res. 2013;76:49-57. - PubMed
  20. Hayes PE, Schulz SC. Beta-blockers in anxiety disorders. J Affect Disord. 1987;13(2):119-130. - PubMed
  21. Adameova A, Abdellatif Y, Dhalla NS. Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease. Can J Physiol Pharmacol. 2009;87(7):493-514. - PubMed
  22. Kirouac GJ. Placing the paraventricular nucleus of the thalamus within the brain circuits that control behavior. Neurosci Biobehav Rev. 2015;56:315-329. - PubMed
  23. Whitworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag. 2005;1(4):291-299. - PubMed
  24. Johnson HM. Anxiety and hypertension: is there a link? A literature review of the comorbidity relationship between anxiety and hypertension. Curr Hypertens Rep. 2019;21(9):66. - PubMed
  25. Zhou Y, Dong Z, A R, et al. The prevalence of impaired glucose regulation in anxiety disorder patients and the relationship with hypothalamic-pituitary-adrenal axis and hypothalamic-pituitary-thyroid axis activity. J Evid Based Med. 2019;12(1):51-55. - PubMed
  26. Stuehr DJ. Mammalian nitric oxide synthases. Biochim Biophys Acta. 1999;1411(2-3):217-230. - PubMed
  27. Vincent SR, Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience. 1992;46(4):755-784. - PubMed
  28. Pitsikas N. The role of nitric oxide (NO) donors in anxiety. Lights and shadows. Nitric Oxide. 2018;77:6-11. - PubMed
  29. Karanth S, Lyson K, McCann SM. Role of nitric oxide in interleukin 2-induced corticotropin-releasing factor release from incubated hypothalami. Proc Natl Acad Sci USA. 1993;90(8):3383-3387. - PubMed
  30. Bauer EP. Serotonin in fear conditioning processes. Behav Brain Res. 2015;277:68-77. - PubMed
  31. Marcinkiewcz CA, Mazzone CM, D'agostino G, et al. Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala. Nature. 2016;537(7618):97-101. - PubMed
  32. Möhler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. 2012;62(1):42-53. - PubMed
  33. DeFeudis FV. gamma-Aminobutyric acid and cardiovascular function. Experientia. 1983;39(8):845-849. - PubMed
  34. Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid Med Cell Longev. 2009;2(2):63-67. - PubMed
  35. Walker DL, Toufexis DJ, Davis M. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol. 2003;463(1-3):199-216. - PubMed
  36. Bourin M. Animal models for screening anxiolytic-like drugs: a perspective. Dialogues Clin Neurosci. 2015;17(3):295-303. - PubMed
  37. Lezak KR, Missig G, Carlezon WA. Behavioral methods to study anxiety in rodents. Dialogues Clin Neurosci. 2017;19(2):181-191. - PubMed
  38. Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res. 2011;63(Suppl 11):S467-S472. - PubMed
  39. Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occup Med. 2015;65(7):601. - PubMed
  40. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19(1):1-15. - PubMed
  41. Harding JW, Sullivan MJ, Hanesworth JM, Cushing LL, Wright JW. Inability of [125I]Sar1, Ile8-angiotensin II to move between the blood and cerebrospinal fluid compartments. J Neurochem. 1988;50(2):554-557. - PubMed
  42. Saavedra JM. Brain and pituitary angiotensin. Endocr Rev. 1992;13(2):329-380. - PubMed
  43. van Thiel BS, Góes Martini A, Te Riet L, et al. Brain renin-angiotensin system: does it exist? Hypertension. 2017;69(6):1136-1144. - PubMed
  44. Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev Physiol. 1987;49:413-435. - PubMed
  45. Saavedra JM, Sánchez-Lemus E, Benicky J. Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications. Psychoneuroendocrinology. 2011;36(1):1-18. - PubMed
  46. Kang YM, Ma Y, Zheng JP, et al. Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovasc Res. 2009;82(3):503-512. - PubMed
  47. Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin N Am. 2009;29(2):247-264. - PubMed
  48. Sparkman NL, Johnson RW. Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. Neuroimmunomodulation. 2008;15(4-6):323-330. - PubMed
  49. Ramirez K, Fornaguera-Trías J, Sheridan JF. Stress-induced microglia activation and monocyte trafficking to the brain underlie the development of anxiety and depression. Curr Top Behav Neurosci. 2017;31:155-172. - PubMed
  50. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56. - PubMed
  51. de Kloet AD, Wang L, Pitra S, et al. A unique “Angiotensin-Sensitive” neuronal population coordinates neuroendocrine, cardiovascular, and behavioral responses to stress. J Neurosci. 2017;37(13):3478-3490. - PubMed
  52. Belcheva I, Georgiev V, Chobanova M, Hadjiivanova C. Behavioral effects of angiotensin II microinjected into CA1 hippocampal area. Neuropeptides. 1997;31(1):60-64. - PubMed
  53. Braszko JJ, Wiśniewski K. Effect of angiotensin II and saralasin on motor activity and the passive avoidance behavior of rats. Peptides. 1988;9(3):475-479. - PubMed
  54. Hoły Z, Wiśniewski K. Examination of the influence of 3,5-DHPG on behavioral activity of angiotensin II. Pol J Pharmacol. 2001;53(3):235-243. - PubMed
  55. Braszko JJ, Kułakowska A, Winnicka MM. Effects of angiotensin II and its receptor antagonists on motor activity and anxiety in rats. J Physiol Pharmacol. 2003;54(2):271-281. - PubMed
  56. Duchemin S, Belanger E, Wu R, Ferland G, Girouard H. Chronic perfusion of angiotensin II causes cognitive dysfunctions and anxiety in mice. Physiol Behav. 2013;109:63-68. - PubMed
  57. Cruickshank JM. The role of beta-blockers in the treatment of hypertension. Adv Exp Med Biol. 2017;956:149-166. - PubMed
  58. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018;36(8):1637-1647. - PubMed
  59. Andersson C, Shilane D, Go AS, et al. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol. 2014;64(3):247-252. - PubMed
  60. Peyracchia M, Errigo D, Raposeiras Rubin S, et al. Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results. J Cardiovasc Med. 2018;19(7):337-343. - PubMed
  61. Joseph P, Swedberg K, Leong DP, Yusuf S. The evolution of β-blockers in coronary artery disease and heart failure (Part 1/5). J Am Coll Cardiol. 2019;74(5):672-682. - PubMed
  62. MERIT-HF. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007. - PubMed
  63. CIBIS-II. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. - PubMed
  64. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349-1355. - PubMed
  65. Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: are all beta-blockers equivalent? Heart Rhythm. 2017;14(1):e41-e44. - PubMed
  66. Sutter JD, Mendes M, Franco OH. Cardioprotective drugs. The ESC Textbook of Preventive Cardiology. Oxford University Press; 2017. - PubMed
  67. Granville-Grossman KL, Turner P. The effect of propranolol on anxiety. Lancet. 1966;1(7441):788-790. - PubMed
  68. Kelly D. Clinical review of beta-blockers in anxiety. Pharmakopsychiatr Neuropsychopharmakol. 1980;13(5):259-266. - PubMed
  69. Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol. 1991;11(6):344-350. - PubMed
  70. Bachmann S, Muller-Werdan U, Huber M, Kasel M, Werdan K, Schmidt H. Positive impact of the β-blocker celiprolol on panic, anxiety, and cardiovascular parameters in patients with mitral valve prolapse syndrome. J Clin Psychopharmacol. 2011;31(6):783-785. - PubMed
  71. Fagerström KO, Hugdahl K, Lundström N. Effect of beta-receptor blockade on anxiety with reference to the three-systems model of phobic behavior. Neuropsychobiology. 1985;13(4):187-193. - PubMed
  72. Liu HH, Milgrom P, Fiset L. Effect of a beta-adrenergic blocking agent on dental anxiety. J Dent Res. 1991;70(9):1306-1308. - PubMed
  73. Falloon IR, Lloyd GG, Harpin RE. The treatment of social phobia. Real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis. 1981;169(3):180-184. - PubMed
  74. AlOkda AM, Nasr MM, Amin SN. Between an ugly truth and a perfect lie: wiping off fearful memories using beta-adrenergic receptors antagonists. J Cell Physiol. 2019;234(5):5722-5727. - PubMed
  75. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008;42(6):503-506. - PubMed
  76. Giustino TF, Fitzgerald PJ, Maren S. Revisiting propranolol and PTSD: memory erasure or extinction enhancement? Neurobiol Learn Mem. 2016;130:26-33. - PubMed
  77. Rosenberg L, Rosenberg M, Sharp S, et al. Does acute propranolol treatment prevent posttraumatic stress disorder, anxiety, and depression in children with burns? J Child Adolesc Psychopharmacol. 2018;28(2):117-123. - PubMed
  78. Leal Santos S, Stackmann M, Muñoz Zamora A, et al. Propranolol decreases fear expression by modulating fear memory traces. Biol Psychiatry. 2021;89:1150-1161. - PubMed
  79. Elsey JWB, Filmer AI, Galvin HR, et al. Reconsolidation-based treatment for fear of public speaking: a systematic pilot study using propranolol. Transl Psychiatry. 2020;10(1):179. - PubMed
  80. Thierrée S, Richa S, Brunet A, et al. Trauma reactivation under propranolol among traumatized Syrian refugee children: preliminary evidence regarding efficacy. Eur J Psychotraumatol. 2020;11(1):1733248. - PubMed
  81. Wu L, Zhang Q, Shu Q, Zhang R, Meng Y. Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients. Medicine. 2019;98(50):e18331. - PubMed
  82. Armstrong C, Kapolowicz MR. A preliminary investigation on the effects of atenolol for treating symptoms of anxiety. Mil Med. 2020;185(11-12):e1954-e1960. - PubMed
  83. Kindt M, Soeter M, Vervliet B. Beyond extinction: erasing human fear responses and preventing the return of fear. Nat Neurosci. 2009;12(3):256-258. - PubMed
  84. Zaidi S, Atrooz F, Valdez D, et al. Protective effect of propranolol and nadolol on social defeat-induced behavioral impairments in rats. Neurosci Lett. 2020;725:134892. - PubMed
  85. Wohleb ES, Hanke ML, Corona AW, et al. β-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J Neurosci. 2011;31(17):6277-6288. - PubMed
  86. Steenen SA, van Wijk AJ, van der Heijden GJMG, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol. 2016;30(2):128-139. - PubMed
  87. Rasmussen DD, Kincaid CL, Froehlich JC. Prazosin prevents increased anxiety behavior that occurs in response to stress during alcohol deprivations. Alcohol Alcohol. 2017;52(1):5-11. - PubMed
  88. Ketenci S, Acet NG, Sarıdoğan GE, Aydın B, Cabadak H, Gören MZ. The neurochemical effects of prazosin treatment on fear circuitry in a rat traumatic stress model. Clin Psychopharmacol Neurosci. 2020;18(2):219-230. - PubMed
  89. Aykac A, Şehirli AÖ, Gören MZ. Evaluation of the effect of prazosin treatment on α-2c adrenoceptor and apoptosis protein levels in the predator scent-induced rat model of post-traumatic stress disorder. J Mol Neurosci. 2020;70(7):1120-1129. - PubMed
  90. Hendrickson RC, Millard SP, Pagulayan KF, Peskind ER, Raskind MA. The relative effects of prazosin on individual PTSD symptoms: evidence for pathophysiologically-related clustering. Chronic Stress. 2021;5:2470547020979780. - PubMed
  91. Hudson N, Burghart S, Reynoldson J, Grauer D. Evaluation of low dose prazosin for PTSD-associated nightmares in children and adolescents. Ment Health Clin. 2021;11(2):45-49. - PubMed
  92. Santivasi W, Taylor E, Christensen A, Strand J. Prazosin for nightmares in serious illness. BMJ Support Palliat Care. 2021. - PubMed
  93. Wilcox CE, Adinoff B, Clifford J, et al. Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder. Neuroimage Clin. 2020;26:102162. - PubMed
  94. Milivojevic V, Angarita GA, Hermes G, Sinha R, Fox HC. Effects of prazosin on provoked alcohol craving and autonomic and neuroendocrine response to stress in alcohol use disorder. Alcohol Clin Exp Res. 2020;44(7):1488-1496. - PubMed
  95. Golda V, Petr R. Animal model of anxiety: the effect of methyldopa in the genetically hypertensive non-obese rats of Koletsky type and in the rats of Wistar strain. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 1990;33(5):529-537. - PubMed
  96. Schweimer J, Fendt M, Schnitzler HU. Effects of clonidine injections into the bed nucleus of the stria terminalis on fear and anxiety behavior in rats. Eur J Pharmacol. 2005;507(1-3):117-124. - PubMed
  97. Mineur YS, Cahuzac EL, Mose TN, et al. Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety- and depression-related behaviors in mice. Neuropsychopharmacology. 2018;43(10):2118-2125. - PubMed
  98. Hoehn-Saric R, Merchant AF, Keyser ML, Smith VK. Effects of clonidine on anxiety disorders. Arch Gen Psychiatry. 1981;38(11):1278-1282. - PubMed
  99. Srour H, Pandya K, Flannery A, Hatton K. Enteral Guanfacine to treat severe anxiety and agitation complicating critical care after cardiac surgery. Semin Cardiothorac Vasc Anesth. 2018;22(4):403-406. - PubMed
  100. Connor DF, Grasso DJ, Slivinsky MD, Pearson GS, Banga A. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents. J Child Adolesc Psychopharmacol. 2013;23(4):244-251. - PubMed
  101. Strawn JR, Compton SN, Robertson B, Albano AM, Hamdani M, Rynn MA. Extended release Guanfacine in pediatric anxiety disorders: a pilot, randomized, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2017;27(1):29-37. - PubMed
  102. Belkin MR, Schwartz TL. Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder. Drugs Context. 2015;4:212286. - PubMed
  103. Aziriova S, Repova Bednarova K, Krajcirovicova K, et al. Doxorubicin-induced behavioral disturbances in rats: protective effect of melatonin and captopril. Pharmacol Biochem Behav. 2014;124:284-289. - PubMed
  104. Repova K, Aziriova S, Kovacova D, et al. Lisinopril reverses behavioural alterations in spontaneously hypertensive rats. Gen Physiol Biophys. 2019;38(3):265-270. - PubMed
  105. Srinivasan J, Suresh B, Ramanathan M. Differential anxiolytic effect of enalapril and losartan in normotensive and renal hypertensive rats. Physiol Behav. 2003;78(4-5):585-591. - PubMed
  106. Feng P, Wu Z, Liu H, et al. Electroacupuncture improved chronic cerebral hypoperfusion-induced anxiety-like behavior and memory impairments in spontaneously hypertensive rats by downregulating the ACE/Ang II/AT1R axis and upregulating the ACE2/Ang-(1-7)/MasR axis. Neural Plast. 2020;2020:9076042. - PubMed
  107. Yu Z, Zhao W, Ding L, Yu Y, Liu J. Anxiolytic effects of ACE inhibitory peptides on the behavior of rats in an elevated plus-maze. Food Funct. 2016;7(1):491-497. - PubMed
  108. Zubenko GS, Nixon RA. Mood-elevating effect of captopril in depressed patients. Am J Psychiatry. 1984;141(1):110-111. - PubMed
  109. Braszko JJ, Karwowska-Polecka W, Halicka D, Gard PR. Captopril and enalapril improve cognition and depressed mood in hypertensive patients. J Basic Clin Physiol Pharmacol. 2003;14(4):323-343. - PubMed
  110. Tashev R, Ivanova M. Involvement of hippocampal angiotensin 1 receptors in anxiety-like behaviour of olfactory bulbectomized rats. Pharmacol Rep. 2018;70(5):847-852. - PubMed
  111. Campos GV, de Souza AMA, Ji H, et al. The Angiotensin Type 1 receptor antagonist losartan prevents ovariectomy-induced cognitive dysfunction and anxiety-like behavior in long Evans rats. Cell Mol Neurobiol. 2020;40(3):407-420. - PubMed
  112. Salmani H, Hosseini M, Baghcheghi Y, Moradi-Marjaneh R, Mokhtari-Zaer A. Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: the role of PPAR-γ activation. Cytokine. 2020;125:154860. - PubMed
  113. Saavedra JM, Armando I, Bregonzio C, et al. A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology. 2006;31(6):1123-1134. - PubMed
  114. Goel R, Bhat SA, Hanif K, Nath C, Shukla R. Angiotensin II receptor blockers attenuate lipopolysaccharide-induced memory impairment by modulation of NF-κB-mediated BDNF/CREB expression and apoptosis in spontaneously hypertensive rats. Mol Neurobiol. 2018;55(2):1725-1739. - PubMed
  115. Benicky J, Sánchez-Lemus E, Honda M, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology. 2011;36(4):857-870. - PubMed
  116. Sánchez-Lemus E, Honda M, Saavedra JM. Angiotensin II AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress. Behav Brain Res. 2012;232(1):84-92. - PubMed
  117. Singh N, Sharma G, Singh N, Hanif K. A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat. Int J Stroke. 2014;9(5):560-568. - PubMed
  118. Gong X, Hu H, Qiao Y, et al. The involvement of renin-angiotensin system in lipopolysaccharide-induced behavioral changes, neuroinflammation, and disturbed insulin signaling. Front Pharmacol. 2019;10:318. - PubMed
  119. Ayyub M, Najmi AK, Akhtar M. Protective effect of Irbesartan an Angiotensin (AT1) receptor antagonist in unpredictable chronic mild stress induced depression in mice. Drug Res. 2017;67(1):59-64. - PubMed
  120. Huber G, Ogrodnik M, Wenzel J, et al. Telmisartan prevents high-fat diet-induced neurovascular impairments and reduces anxiety-like behavior. J Cereb Blood Flow Metab. 2021;17:271678X211003497. - PubMed
  121. Shad MU. Is there an association between anxiety symptoms and valsartan treatment? J Affect Disord. 2020;261:111-112. - PubMed
  122. Khoury NM, Marvar PJ, Gillespie CF, et al. The renin-angiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms. J Clin Psychiatry. 2012;73(6):849-855. - PubMed
  123. Ho JK, Nation DA. Alzheimer's disease neuroimaging initiative. Memory is preserved in older adults taking AT1 receptor blockers. Alzheimer's Res Ther. 2017;9(1):33. - PubMed
  124. Almeida-Santos AF, Kangussu LM, Moreira FA, Santos RAS, Aguiar DC, Campagnole-Santos MJ. Anxiolytic- and antidepressant-like effects of angiotensin-(1-7) in hypertensive transgenic (mRen2)27 rats. Clin Sci. 2016;130(14):1247-1255. - PubMed
  125. Bild W, Ciobica A. Angiotensin-(1-7) central administration induces anxiolytic-like effects in elevated plus maze and decreased oxidative stress in the amygdala. J Affect Disord. 2013;145(2):165-171. - PubMed
  126. Martins Lima A, Xavier CH, Ferreira AJ, et al. Activation of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis attenuates the cardiac reactivity to acute emotional stress. Am J Physiol Heart Circ Physiol. 2013;305(7):H1057-H1067. - PubMed
  127. Oscar CG, Müller-Ribeiro FC, de Castro LG, et al. Angiotensin-(1-7) in the basolateral amygdala attenuates the cardiovascular response evoked by acute emotional stress. Brain Res. 2015;1594:183-189. - PubMed
  128. Wang L, de Kloet AD, Pati D, et al. Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors. Neuropharmacology. 2016;105:114-123. - PubMed
  129. Kangussu LM, Almeida-Santos AF, Moreira FA, et al. Reduced anxiety-like behavior in transgenic rats with chronically overproduction of angiotensin-(1-7): role of the Mas receptor. Behav Brain Res. 2017;331:193-198. - PubMed
  130. Moura Santos D, Ribeiro Marins F, Limborço-Filho M, et al. Chronic overexpression of angiotensin-(1-7) in rats reduces cardiac reactivity to acute stress and dampens anxious behavior. Stress. 2017;20(2):189-196. - PubMed
  131. López-Rubalcava C, Paez-Martinez N, Oikawa J. Blockade of corticosteroid receptors induces anxiolytic-like effects in streptozotocin-induced diabetic mice, and synergizes with diazepam. Behav Pharmacol. 2013;24(4):320-327. - PubMed
  132. Fox LC, Davies DR, Scholl JL, Watt MJ, Forster GL. Differential effects of glucocorticoid and mineralocorticoid antagonism on anxiety behavior in mild traumatic brain injury. Behav Brain Res. 2016;312:362-365. - PubMed
  133. Hlavacova N, Jezova D. Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. Endocr Regul. 2008;42(4):147-153. - PubMed
  134. Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab. 2011;96(9):2904-2911. - PubMed
  135. Revuelta-López E, Núñez J, Gastelurrutia P, et al. Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. ESC Heart Fail. 2020;7(2):559-566. - PubMed
  136. Dereli S, Kılınçel O, Çerik İB, Kaya A. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction. Acta Cardiol. 2020;18:1-9. - PubMed
  137. Guo Y, Zou G, Qi K, et al. Simvastatin impairs hippocampal synaptic plasticity and cognitive function in mice. Mol Brain. 2021;14(1):41. - PubMed
  138. Kilic FS, Ozatik Y, Kaygisiz B, Baydemir C, Erol K. Acute antidepressant and anxiolytic effects of simvastatin and its mechanisms in rats. Neurosciences. 2012;17(1):39-43. - PubMed
  139. Yan J, Huang J, Liu A, et al. Atorvastatin improves motor function, anxiety and depression by NOX2-mediated autophagy and oxidative stress in MPTP-lesioned mice. Aging. 2020;13(1):831-845. - PubMed
  140. Mijailovic N, Selakovic D, Joksimovic J, et al. The anxiolytic effects of atorvastatin and simvastatin on dietary-induced increase in homocysteine levels in rats. Mol Cell Biochem. 2019;452(1-2):199-217. - PubMed
  141. Citraro R, Chimirri S, Aiello R, et al. Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. Epilepsia. 2014;55(8):1284-1291. - PubMed
  142. Evangelista FF, Costa-Ferreira W, Mantelo FM, et al. Rosuvastatin revert memory impairment and anxiogenic-like effect in mice infected with the chronic ME-49 strain of Toxoplasma gondii. PLOS One. 2021;16(4):e0250079. - PubMed
  143. Okudan N, Belviranli M. High dose simvastatin and rosuvastatin impair cognitive abilities of healthy rats via decreasing hippocampal neurotrophins and irisin. Brain Res Bull. 2020;165:81-89. - PubMed
  144. Mirzaei E, Mirjalili M, Jahangard L, et al. Influence of simvastatin as augmentative therapy in the treatment of generalized anxiety disorder: a pilot randomized, placebo-controlled study. Neuropsychobiology. 2021;80(3):242-252. - PubMed
  145. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf. 2007;30(3):195-201. - PubMed
  146. Cham S, Koslik HJ, Golomb BA. Mood, personality, and behavior changes during treatment with statins: a case series. Drug Saf Case Rep. 2016;3(1):1. - PubMed
  147. Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM. 2004;97(4):229-235. - PubMed
  148. Duits N, Bos FM. Depressive symptoms and cholesterol-lowering drugs. Lancet. 1993;341(8837):114. - PubMed
  149. Korhonen MJ, Pentti J, Hartikainen J, Kivimäki M, Vahtera J. Somatic symptoms of anxiety and nonadherence to statin therapy. Int J Cardiol. 2016;214:493-499. - PubMed
  150. Molero Y, Cipriani A, Larsson H, Lichtenstein P, D'Onofrio BM, Fazel S. Associations between statin use and suicidality, depression, anxiety, and seizures: a Swedish total-population cohort study. Lancet Psychiatry. 2020;7(11):982-990. - PubMed
  151. Sarahian N, Mohammadi MT, Darabi S, Faghihi N. Fenofibrate protects the neurovascular unit and ameliorates plasma corticosterone levels in pentylenetetrazole-induced kindling seizure in mice. Brain Res. 2021;1758:147343. - PubMed
  152. Mirza R, Sharma B. Selective modulator of peroxisome proliferator-activated receptor-α protects propionic acid induced autism-like phenotypes in rats. Life Sci. 2018;214:106-117. - PubMed
  153. Mirza R, Sharma B. Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. Brain Res Bull. 2019;147:36-46. - PubMed
  154. Locci A, Pinna G. Stimulation of peroxisome proliferator-activated receptor-α by N-palmitoylethanolamine engages allopregnanolone biosynthesis to modulate emotional behavior. Biol Psychiatry. 2019;85(12):1036-1045. - PubMed
  155. Aziriova S, Repova K, Krajcirovicova K, et al. Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension. J Physiol Pharmacol. 2016;67(6):895-902. - PubMed
  156. Krajcirovicova K, Aziriova S, Baka T, et al. Ivabradine does not impair anxiety-like behavior and memory in both healthy and L-NAME-induced hypertensive rats. Physiol Res. 2018;67(Supplum 4):S655-S664. - PubMed
  157. Riccioni G, Masciocco L, Benvenuto A, et al. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study. Pharmacology. 2013;92(5-6):276-280. - PubMed
  158. Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014;31(9):961-974. - PubMed
  159. Riccioni G, Prencipe G, Benvenuto A, et al. Ivabradine improves all aspects of quality of life assessed with the 36-item short form health survey in subjects with chronic ischemic heart disease compared with beta-blockers. Pharmacology. 2013;91(1-2):35-38. - PubMed
  160. Fulga IG, Stroescu V. Experimental research on the effect of calcium channel blockers nifedipine and verapamil on the anxiety in mice. Rom J Physiol. 1997;34(1-4):127-136. - PubMed
  161. Joseph A, Thuy TTT, Thanh LT, Okada M. Antidepressive and anxiolytic effects of ostruthin, a TREK-1 channel activator. PLOS One. 2018;13(8):e0201092. - PubMed
  162. Klein E, Geraci M, Uhde TW. Inefficacy of single-dose nifedipine in the treatment of phobic anxiety. Isr J Psychiatry Relat Sci. 1990;27(2):119-123. - PubMed
  163. Krystal AD, Sutherland J, Hochman DW. Loop diuretics have anxiolytic effects in rat models of conditioned anxiety. PLOS One. 2012;7(4):e35417. - PubMed
  164. Farajdokht F, Babri S, Karimi P, Alipour MR, Bughchechi R, Mohaddes G. Chronic ghrelin treatment reduced photophobia and anxiety-like behaviors in nitroglycerin- induced migraine: role of pituitary adenylate cyclase-activating polypeptide. Eur J Neurosci. 2017;45(6):763-772. - PubMed
  165. Taheri P, Mohammadi F, Nazeri M, et al. Nitric oxide role in anxiety-like behavior, memory and cognitive impairments in animal model of chronic migraine. Heliyon. 2020;6(12):e05654. - PubMed
  166. Magyar-Russell G, Thombs BD, Cai JX, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res. 2011;71(4):223-231. - PubMed
  167. Jaillon P. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet. 1980;5(4):365-376. - PubMed
  168. Mah GT, Tejani AM, Musini VM. Methyldopa for primary hypertension. Cochrane Database Syst Rev. 2009;4:CD003893. - PubMed
  169. Garrett BN, Kaplan NM. Clonidine in the treatment of hypertension. J Cardiovasc Pharmacol. 1980;2(Suppl 1):S61-S71. - PubMed
  170. Sorkin EM, Heel RC. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs. 1986;31(4):301-336. - PubMed
  171. Neil MJ. Clonidine: clinical pharmacology and therapeutic use in pain management. Curr Clin Pharmacol. 2011;6(4):280-287. - PubMed
  172. Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018;6:CD007990. - PubMed
  173. Childress A, Hoo-Cardiel A, Lang P. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents. Expert Opin Pharmacother. 2020;21(4):417-426. - PubMed
  174. Vian J, Pereira C, Chavarria V, et al. The renin-angiotensin system: a possible new target for depression. BMC Med. 2017;15(1):144. - PubMed
  175. Brownstein DJ, Salagre E, Köhler C, et al. Blockade of the angiotensin system improves mental health domain of quality of life: a meta-analysis of randomized clinical trials. Aust N Z J Psychiatry. 2018;52(1):24-38. - PubMed
  176. Regulski M, Regulska K, Stanisz BJ, et al. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr Pharm Des. 2015;21(13):1764-1775. - PubMed
  177. Repová-Bednárová K, Aziriová S, Hrenák J, et al. Effect of captopril and melatonin on fibrotic rebuilding of the aorta in 24 hour light-induced hypertension. Physiol Res. 2013;62(Suppl 1):S135-S141. - PubMed
  178. Simko F, Pechanova O, Repova K, et al. Lactacystin-induced model of hypertension in rats: effects of melatonin and captopril. Int J Mol Sci. 2017;18(8). - PubMed
  179. Simko F, Pechanova O, Krajcirovicova K, et al. Effects of captopril, spironolactone, and simvastatin on the cardiovascular system of non-diseased Wistar rats. Int J Cardiol. 2015;190:128-130. - PubMed
  180. Simko F, Pechanova O, Pelouch V, et al. Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril. J Hypertens. 2010;28(Suppl 1):S13-S18. - PubMed
  181. Simko F, Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol Res. 2000;49(1):37-46. - PubMed
  182. Simko F, Simko J. Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol Res. 1999;48(1):1-8. - PubMed
  183. Simko F, Pechanova O, Repova Bednarova K, et al. Hypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin. Mediators of Inflamm. 2014;2014:703175. - PubMed
  184. CAPP Study Group. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. The Captopril Prevention Project (CAPP) Study Group. Curr Hypertens Rep. 1999;1(6):466-467. - PubMed
  185. UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):713-720. - PubMed
  186. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-677. - PubMed
  187. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333(25):1670-1676. - PubMed
  188. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-1435. - PubMed
  189. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303-310. - PubMed
  190. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685-691. - PubMed
  191. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. - PubMed
  192. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368(9535):581-588. - PubMed
  193. Saavedra JM. Beneficial effects of Angiotensin II receptor blockers in brain disorders. Pharmacol Res. 2017;125(Pt A):91-103. - PubMed
  194. Genaro K, Fabris D, Fachim HA, Prado WA. Angiotensin AT1 receptors modulate the anxiogenic effects of angiotensin (5-8) injected into the rat ventrolateral periaqueductal gray. Peptides. 2017;96:8-14. - PubMed
  195. Guimond MO, Gallo-Payet N. The Angiotensin II type 2 receptor in brain functions: an update. Int J Hypertens. 2012;2012:351758. - PubMed
  196. Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev. 2018;98(1):505-553. - PubMed
  197. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-717. - PubMed
  198. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321. - PubMed
  199. Grossman E, Nadler M, Sharabi Y, Thaler M, Shachar A, Shamiss A. Antianxiety treatment in patients with excessive hypertension. Am J Hypertens. 2005;18(9 Pt 1):1174-1177. - PubMed
  200. Omboni S, Volpe M. Angiotensin receptor blockers versus angiotensin converting enzyme inhibitors for the treatment of arterial hypertension and the role of olmesartan. Adv Ther. 2019;36(2):278-297. - PubMed
  201. Simko F, Simko J, Fabryova M. ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle. Cardiovasc Drugs Ther. 2003;17(3):287-290. - PubMed
  202. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. - PubMed
  203. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759-766. - PubMed
  204. Tokmakova M, Solomon SD. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Curr Opin Cardiol. 2006;21(4):268-272. - PubMed
  205. Boal AH, Smith DJ, McCallum L, et al. Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood disorders. Hypertension. 2016;68(5):1132-1138. - PubMed
  206. Anil Kumar KV, Nagwar S, Thyloor R, Satyanarayana S. Anti-stress and nootropic activity of drugs affecting the renin-angiotensin system in rats based on indirect biochemical evidence. J Renin Angiotensin Aldosterone Syst. 2015;16(4):801-812. - PubMed
  207. Ping G, Qian W, Song G, Zhaochun S. Valsartan reverses depressive/anxiety-like behavior and induces hippocampal neurogenesis and expression of BDNF protein in unpredictable chronic mild stress mice. Pharmacol Biochem Behav. 2014;124:5-12. - PubMed
  208. Hrenak J, Paulis L, Simko F. Angiotensin A/Alamandine/MrgD Axis: another clue to understanding cardiovascular pathophysiology. Int J Mol Sci. 2016;17(7). - PubMed
  209. Simko F, Baka T. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat? Clin Sci. 2021;135(8):1009-1014. - PubMed
  210. Steckelings UM, Sumners C. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clin Sci. 2020;134(22):2987-3006. - PubMed
  211. Chaves GZ, Caligiorne SM, Santos RA, Khosla MC, Campagnole-Santos MJ. Modulation of the baroreflex control of heart rate by angiotensin-(1-7) at the nucleus tractus solitarii of normotensive and spontaneously hypertensive rats. J Hypertens. 2000;18(12):1841-1848. - PubMed
  212. Guimaraes PS, Oliveira MF, Braga JF, et al. Increasing angiotensin-(1-7) levels in the brain attenuates metabolic syndrome-related risks in fructose-fed rats. Hypertension. 2014;63(5):1078-1085. - PubMed
  213. Guimaraes PS, Santiago NM, Xavier CH, et al. Chronic infusion of angiotensin-(1-7) into the lateral ventricle of the brain attenuates hypertension in DOCA-salt rats. Am J Physiol Heart Circ Physiol. 2012;303(3):H393-H400. - PubMed
  214. Nautiyal M, Shaltout HA, de Lima DC, do Nascimento K, Chappell MC, Diz DI. Central angiotensin-(1-7) improves vagal function independent of blood pressure in hypertensive (mRen2)27 rats. Hypertension. 2012;60(5):1257-1265. - PubMed
  215. Xue B, Zhang Z, Beltz TG, Guo F, Hay M, Johnson AK. Estrogen regulation of the brain renin-angiotensin system in protection against angiotensin II-induced sensitization of hypertension. Am J Physiol Heart Circ Physiol. 2014;307(2):H191-H198. - PubMed
  216. Moreno-Santos B, Marchi-Coelho C, Costa-Ferreira W, Crestani CC. Angiotensinergic receptors in the medial amygdaloid nucleus differently modulate behavioral responses in the elevated plus-maze and forced swimming test in rats. Behav Brain Res. 2021;397:112947. - PubMed
  217. Grundy HM, Simpson SA, Tait JF. Isolation of a highly active mineralocorticoid from beef adrenal extract. Nature. 1952;169(4306):795-796. - PubMed
  218. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237(4812):268-275. - PubMed
  219. Young MJ, Rickard AJ. Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Mol Cell Endocrinol. 2012;350(2):248-255. - PubMed
  220. Dettli L, Spring P. Therapy with combinations of diuretic agents: comparative studies. Ann N Y Acad Sci. 1966;139(2):471-480. - PubMed
  221. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53-e90. - PubMed
  222. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839-845. - PubMed
  223. Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39(3):257-263. - PubMed
  224. Geerling JC, Loewy AD. Aldosterone in the brain. Am J Physiol Renal Physiol. 2009;297(3):F559-F576. - PubMed
  225. Hlavacova N, Jezova D. Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav. 2008;54(1):90-97. - PubMed
  226. Sonino N, Fallo F, Fava GA. Psychological aspects of primary aldosteronism. Psychother Psychosom. 2006;75(5):327-330. - PubMed
  227. Khurshid KA, Weaver ME. Conn's syndrome presenting as depression. Am J Psychiatry. 2005;162(6):1226. - PubMed
  228. Sonino N, Tomba E, Genesia ML, et al. Psychological assessment of primary aldosteronism: a controlled study. J Clin Endocrinol Metab. 2011;96(6):E878-E883. - PubMed
  229. Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab. 2010;95(3):1360-1364. - PubMed
  230. McMurray JJV. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17(3):242-247. - PubMed
  231. Simko F, Dukat A. Inhibition of neprilysin - new horizon in heart failure therapy. Cardiol Lett. 2016;25(4):273-276. - PubMed
  232. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol. 2012;60(22):2305-2312. - PubMed
  233. Vanneste Y, Michel A, Dimaline R, Najdovski T, Deschodt-Lanckman M. Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site. Biochem J. 1988;254(2):531-537. - PubMed
  234. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61. - PubMed
  235. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to determine impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15(9):1062-1073. - PubMed
  236. D'Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail. 2017;19(6):710-717. - PubMed
  237. Nougué H, Pezel T, Picard F, et al. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail. 2019;21(5):598-605. - PubMed
  238. Gregoriou GC, Patel SD, Winters BL, Bagley EE. Neprilysin controls the synaptic activity of neuropeptides in the intercalated cells of the Amygdala. Mol Pharmacol. 2020;98(4):454-461. - PubMed
  239. Meyer T, Herrmann-Lingen C. Natriuretic peptides in anxiety and panic disorder. Vitam Horm. 2017;103:131-145. - PubMed
  240. Marazziti D, Barberi FM, Mucci F, Maglio A, Dell'Oste V, Dell'Osso L. The emerging role of atrial natriuretic peptide in psychiatry. Curr Med Chem. 2020;28:69-79. - PubMed
  241. Meyer T, Herrrmann-Lingen C, Chavanon ML, et al. Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational DIAST-CHF study. Clin Res Cardiol. 2015;104(7):574-581. - PubMed
  242. Wiedemann K, Jahn H, Kellner M. Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behaviour. Exp Clin Endocrinol Diabetes. 2000;108(1):5-13. - PubMed
  243. Ströhle A, Feller C, Strasburger CJ, Heinz A, Dimeo F. Anxiety modulation by the heart? Aerobic exercise and atrial natriuretic peptide. Psychoneuroendocrinology. 2006;31(9):1127-1130. - PubMed
  244. Iftikhar K, Siddiq A, Baig SG, Zehra S. Substance P: a neuropeptide involved in the psychopathology of anxiety disorders. Neuropeptides. 2020;79:101993. - PubMed
  245. Hoppe JM, Frick A, Åhs F, et al. Association between amygdala neurokinin-1 receptor availability and anxiety-related personality traits. Transl Psychiatry. 2018;8(1):168. - PubMed
  246. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21(2):138-167. - PubMed
  247. Daukantaitė D, Tellhed U, Maddux RE, Svensson T, Melander O. Five-week yin yoga-based interventions decreased plasma adrenomedullin and increased psychological health in stressed adults: a randomized controlled trial. PLOS One. 2018;13(7):e0200518. - PubMed
  248. Kong DG, Gao H, Lu YQ, et al. Anxiety disorders are associated with increased plasma adrenomedullin level and left ventricular hypertrophy in patients with hypertension. Clin Exp Hypertens. 2014;36(1):27-31. - PubMed
  249. Fernández AP, Serrano J, Tessarollo L, Cuttitta F, Martínez A. Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions. Proc Natl Acad Sci USA. 2008;105(34):12581-12586. - PubMed
  250. Rouhiainen A, Kulesskaya N, Mennesson M, et al. The bradykinin system in stress and anxiety in humans and mice. Sci Rep. 2019;9(1):19437. - PubMed
  251. Câmara AB, Brandão IA. Neural receptors associated with depression: a systematic review of the past 10 years. CNS Neurol Disord Drug Targets. 2020;19(6):417-436. - PubMed
  252. Luo H, Wu PF, Cao Y, et al. Angiotensin-converting enzyme inhibitor rapidly ameliorates depressive-type behaviors via bradykinin-dependent activation of mammalian target of rapamycin complex 1. Biol Psychiatry. 2020;88(5):415-425. - PubMed
  253. Istvan ES. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J. 2002;144(6 Suppl):S27-S32. - PubMed
  254. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407-415. - PubMed
  255. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229-243. - PubMed
  256. Simko F. Statins: a perspective for left ventricular hypertrophy treatment. Eur J Clin Invest. 2007;37(9):681-691. - PubMed
  257. Simko F, Pechanova O, Pelouch V, et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J Hypertens Suppl. 2009;27(6):S5-S10. - PubMed
  258. Simko F, Matuskova J, Luptak I, et al. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci. 2004;74(10):1211-1224. - PubMed
  259. Apostolopoulou M, Corsini A, Roden M. The role of mitochondria in statin-induced myopathy. Eur J Clin Invest. 2015;45(7):745-754. - PubMed
  260. Shrivastava S, Pucadyil TJ, Paila YD, Ganguly S, Chattopadhyay A. Chronic cholesterol depletion using statin impairs the function and dynamics of human serotonin(1A) receptors. Biochemistry. 2010;49(26):5426-5435. - PubMed
  261. Wallner B, Machatschke IH. The evolution of violence in men: the function of central cholesterol and serotonin. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(3):391-397. - PubMed
  262. Golomb BA, Stattin H, Mednick S. Low cholesterol and violent crime. J Psychiatr Res. 2000;34(4):301-309. - PubMed
  263. Messaoud A, Mensi R, Mrad A, et al. Is low total cholesterol levels associated with suicide attempt in depressive patients? Ann Gen Psychiatry. 2017;16:20. - PubMed
  264. Suneson K, Asp M, Träskman-Bendz L, Westrin Å, Ambrus L, Lindqvist D. Low total cholesterol and low-density lipoprotein associated with aggression and hostility in recent suicide attempters. Psychiatry Res. 2019;273:430-434. - PubMed
  265. Garland MR, Hallahan B, McNamara M, et al. Lipids and essential fatty acids in patients presenting with self-harm. Br J Psychiatry. 2007;190:112-117. - PubMed
  266. Dietschy JM. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem. 2009;390(4):287-293. - PubMed
  267. Pfrieger FW, Ungerer N. Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res. 2011;50(4):357-371. - PubMed
  268. Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004;45(8):1375-1397. - PubMed
  269. Muldoon MF, Kaplan JR, Manuck SB, Mann JJ. Effects of a low-fat diet on brain serotonergic responsivity in cynomolgus monkeys. Biol Psychiatry. 1992;31(7):739-742. - PubMed
  270. Kaplan JR, Manuck SB, Shively C. The effects of fat and cholesterol on social behavior in monkeys. Psychosom Med. 1991;53(6):634-642. - PubMed
  271. Markianos M, Koutsis G, Evangelopoulos ME, Sfagos C. Serum total cholesterol correlates positively to central serotonergic turnover in male but not in female subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):527-531. - PubMed
  272. Mann JJ, Arango V, Marzuk PM, Theccanat S, Reis DJ. Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br J Psychiatry Suppl. 1989;8:7-14. - PubMed
  273. Lidberg L, Asberg M, Sundqvist-Stensman UB. 5-Hydroxyindoleacetic acid levels in attempted suicides who have killed their children. Lancet. 1984;2(8408):928. - PubMed
  274. Lidberg L, Tuck JR, Asberg M, Scalia-Tomba GP, Bertilsson L. Homicide, suicide and CSF 5-HIAA. Acta Psychiatr Scand. 1985;71(3):230-236. - PubMed
  275. Liu A, Patterson AD, Yang Z, et al. Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics. Drug Metab Dispos. 2009;37(6):1157-1163. - PubMed
  276. Silva FC, Paiva FA, Müller-Ribeiro FC, et al. Chronic treatment with ivabradine does not affect cardiovascular autonomic control in rats. Front Physiol. 2016;7:305. - PubMed
  277. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-885. - PubMed
  278. Baka T, Simko F. Ivabradine modulates the autonomic nervous system by affecting the “little brain” of the heart: a hypothesis. Med Hypotheses. 2019;129:109253. - PubMed
  279. Baka T, Simko F. Ivabradine reversed nondipping heart rate in rats with l-NAME-induced hypertension. Clin Exp Pharmacol Physiol. 2019;46(6):607-610. - PubMed
  280. Heusch G, Kleinbongard P. Ivabradine: cardioprotection by and beyond heart rate reduction. Drugs. 2016;76(7):733-740. - PubMed
  281. Simko F, Baka T, Poglitsch M, et al. Effect of ivabradine on a hypertensive heart and the renin-angiotensin-aldosterone system in L-NAME-induced hypertension. Int J Mol Sci. 2018;19(10):3017. - PubMed
  282. Simko F, Baka T. Chronotherapy as a potential approach to hypertensive patients with elevated heart rate? Br J Clin Pharmacol. 2019;85(8):1861-1862. - PubMed
  283. Simko F, Baka T. Ivabradine and blood pressure reduction: underlying pleiotropic mechanisms and clinical implications. Front Cardiovasc Med. 2021;8:607998. - PubMed
  284. Oliphant CS, Owens RE, Bolorunduro OB, Jha SK. Ivabradine: a review of labeled and off-label uses. Am J Cardiovasc Drugs. 2016;16(5):337-347. - PubMed
  285. Simko F, Baka T, Repova K, et al. Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury. Fundam Clin Pharmacol. 2021;35(4):744-748. - PubMed
  286. Cavalcante TMB, De Melo JMA J, Lopes LB, et al. Ivabradine possesses anticonvulsant and neuroprotective action in mice. Biomed Pharmacother. 2019;109:2499-2512. - PubMed
  287. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. - PubMed
  288. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44-e164. - PubMed
  289. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-e267. - PubMed
  290. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. - PubMed
  291. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol. 2003;39(2):187-192. - PubMed
  292. Meena J, Bagga A. Current perspectives in management of edema in nephrotic syndrome. Indian J Pediatr. 2020;87(8):633-640. - PubMed
  293. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228. - PubMed
  294. O'gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140. - PubMed
  295. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. - PubMed
  296. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776-803. - PubMed
  297. Defibrillators | NHLBI, NIH. - PubMed
  298. Hammill SC, Kremers MS, Kadish AH, et al. Review of the ICD Registry's third year, expansion to include lead data and pediatric ICD procedures, and role for measuring performance. Heart Rhythm. 2009;6(9):1397-1401. - PubMed
  299. Kamphuis HCM, De Leeuw JRJ, Derksen R, Hauer R, Winnubst JaM. A 12-month quality of life assessment of cardiac arrest survivors treated with or without an implantable cardioverter defibrillator. Europace. 2002;4(4):417-425. - PubMed
  300. Sears SF, Burns JL, Handberg E, Sotile WM, Conti JB. Young at heart: understanding the unique psychosocial adjustment of young implantable cardioverter defibrillator recipients. Pacing Clin Electrophysiol. 2001;24(7):1113-1117. - PubMed
  301. Sears SF, Todaro JF, Lewis TS, Sotile W, Conti JB. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol. 1999;22(7):481-489. - PubMed
  302. Burke JL, Hallas CN, Clark-Carter D, White D, Connelly D. The psychosocial impact of the implantable cardioverter defibrillator: a meta-analytic review. Br J Health Psychol. 2003;8(Pt 2):165-178. - PubMed
  303. Andersen CM, Theuns DAMJ, Johansen JB, Pedersen SS. Anxiety, depression, ventricular arrhythmias and mortality in patients with an implantable cardioverter defibrillator: 7 years' follow-up of the MIDAS cohort. Gen Hosp Psychiatry. 2020;66:154-160. - PubMed
  304. Thylén I, Dekker RL, Jaarsma T, Strömberg A, Moser DK. Characteristics associated with anxiety, depressive symptoms, and quality-of-life in a large cohort of implantable cardioverter defibrillator recipients. J Psychosom Res. 2014;77(2):122-127. - PubMed
  305. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933-1940. - PubMed
  306. Sears SF, Sowell LD, Kuhl EA, et al. The ICD shock and stress management program: a randomized trial of psychosocial treatment to optimize quality of life in ICD patients. Pacing Clin Electrophysiol. 2007;30(7):858-864. - PubMed
  307. Frizelle DJ, Lewin RJ, Kaye G, et al. Cognitive-behavioural rehabilitation programme for patients with an implanted cardioverter defibrillator: a pilot study. Br J Health Psychol. 2004;9(Pt 3):381-392. - PubMed
  308. Senthilkumar A, Subitha L, Saravanan E, Giriyappa DK, Satheesh S, Menon V. Depressive symptoms and health-related quality of life in patients with cardiovascular diseases attending a tertiary care hospital, Puducherry-a cross-sectional study. J Neurosci Rural Pract. 2021;12(2):376-381. - PubMed
  309. Korosi B, Laszlo A, Tabak A, et al. The impact of currently recommended antihypertensive therapy on depression and other psychometric parameters: preliminary communication. Neuropsychopharmacol Hung. 2017;19(1):11-22. - PubMed
  310. Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol. 2010;65(5):565-570. - PubMed
  311. Hrenak J, Simko F. Renin-angiotensin system: an important player in the pathogenesis of acute respiratory distress syndrome. Int J Mol Sci. 2020;21(21). - PubMed
  312. De Pinieux G, Chariot P, Ammi-Saïd M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996;42(3):333-337. - PubMed
  313. Palomäki A, Malminiemi K, Metsä-Ketelä T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. FEBS Lett. 1997;410(2-3):254-258. - PubMed
  314. Simko F, Hrenak J, Dominguez-Rodriguez A, Reiter RJ. Melatonin as a putative protection against myocardial injury in COVID-19 infection. Expert Rev Clin Pharmacol. 2020;13(9):921-924. - PubMed
  315. Azevedo RB, Botelho BG, Hollanda J, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35(1):4-11. - PubMed
  316. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020;35(5):744-748. - PubMed
  317. Alomari SO, Abou-Mrad Z, Bydon A. COVID-19 and the central nervous system. Clin Neurol Neurosurg. 2020;198:106116. - PubMed
  318. Kamal AT, Sukhia RH, Ghandhi D, Sukhia HR. Stress and anxiety among dental practitioners during the COVID-19 pandemic: a cross-sectional survey. Dent Med Probl. 2021;58:139-146. - PubMed
  319. Conti C, Fontanesi L, Lanzara R, Rosa I, Doyle RL, Porcelli P. Burnout status of Italian healthcare workers during the first COVID-19 pandemic peak period. Healthcare. 2021;9(5). - PubMed
  320. Gilleen J, Santaolalla A, Valdearenas L, Salice C, Fusté M. Impact of the COVID-19 pandemic on the mental health and well-being of UK healthcare workers. BJPsych Open. 2021;7(3):e88. - PubMed
  321. Yu A, Wilkes M, Iosif AM, et al. Exploring the relationships between resilience and news monitoring with COVID distress in health profession students. Acad Psychiatry. 2021;45:566-574. - PubMed
  322. Martínez-López JÁ, Lázaro-Pérez C, Gómez-Galán J. Death anxiety in social workers as a consequence of the COVID-19 pandemic. Behav Sci. 2021;11(5). - PubMed
  323. Mazza MG, De Lorenzo R, Conte C, et al. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594-600. - PubMed
  324. Simko F, Pechanova O, Repova Bednarova K, et al. Hypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin. Mediators of Inflamm. 2014;2014:703175. - PubMed

Publication Types

Grant support